Videos

Plasma donation

The Power of Plasma Donation

From the PPTA Global Board of Directors: "Thank you, plasma donors!"

From PPTA:
"Thank you, plasma donors!"

Spotlight on Plasma Part One:
Together We Are Stronger

The Gift of Life

Becoming a Plasma Donor

Plasma Protein Therapies

Doctors Praise Plasma Protein Therapies

Saving and Improving Lives
Celebrating PPTA's 20th Aniversary

PPTA Webinars

“Introduction to the Global Journey of Plasma"

Download in PDF

"Plasma 101"

PPTA webinar on unique patient access challenges to plasma-derived medicinal products in COVID times

Highlights from the EP roundtable event “Ensuring Appropriate Patient Access to Plasma-Derived Medicinal Products”

Highlights from the EP roundtable event “Europe’s need for more plasma- Before, during, after Covid-19”

PPTA Podcasts

Plasma is Life podcast series episode 3:
Dr. Toby Simon, CSL Behring

Plasma is Life podcast series episode 2:
U.S. Election 2020 Wrap-Up

Plasma is Life podcast series episode 1:
Dr. Karen Etchberger, CSL Behring

Global Plasma Summit

Welcome to the Global Plasma Summit

Combating COVID-19 Industry Spotlight: CoVIg-19 Plasma Alliance

Plasma: An Overview

Combating COVID-19 Industry Spotlight: Emergent

Combating COVID-19 Industry Spotlight: Grifols

Experts on Coronavirus: The Virus, The Disease, Prevention and Treatment

Patient Perspectives on COVID-19
and Access to Care

Combating COVID-19 Industry Spotlight: Kedrion

Keynote Address – Stella Kyriakides, European Commissioner for Health and Food Safety

Keynote Address – Admiral Brett Giroir, MD, U.S. Department of Health & Human Services Assistant Secretary for Health

Presentation of the 2020 Joachim Hilfenhaus Award

Presentation of the 2020 Robert W. Reilly Award

Media and Information

PPTA News

Study Shows Immunoglobulin Therapy is “Critical and Cost-Effective” in Treating CVID +

The journal publication, “Immunoglobulin Replacement Therapy is critical and cost-effective in increasing life expectancy and quality of life in patients suffering from Common Variable Immunodeficiency Disorders (CVID): A health-economic assessment,” is authored by Professor Philippe van Wilder with the Université libre de Bruxelles and Professor Esther de Vries of Tilburg University and offers a health economic model to estimate the value of treatment with IG therapy for CVID patients.
Read More
New position statement by CHMP regarding donor deferral criteria for sexual behaviour helps assessment of PMFs +

The International Plasma and Fractionation Association and the Plasma Protein Therapeutics Association are pleased with the recent publication by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) "CHMP Position statement on quality and safety assessment for the Plasma Master File (PMF) certification with regard to donor deferral criteria for sexual risk behaviour," as such a position was highly needed, especially regarding men-having-sex-with-men (MSM). It clarifies that the application of these nationally defined deferral periods will from now on also be considered when assessing appropriateness of locally collected plasma to be included in a PMF.
Read More
Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients +

February 25, 2021 (Annapolis, MD) - The Plasma Protein Therapeutics Association (PPTA) welcomes the decision of the UK government to lift a two decades old ban on the use of UK-donated plasma for the manufacture of immunoglobulins, following a scientific review conducted by the Medicines and Healthcare Products Regulatory Agency. The ban was imposed in 1998 to mitigate the spread of variant Creutzfeldt Jakob Disease (vCJD), but experts have now concluded that the use of UK-sourced plasma to manufacture immunoglobulins is safe and can recommence, supported by a set of robust safety measures.
Read More
Human Plasma Donations Remain Important During COVID-19 Pandemic +

In a recent communication, the U.S. Food and Drug Administration (FDA) limits the collection and use of COVID-19 convalescent plasma authorized under Emergency Use Authorization for the treatment of hospitalized patients with COVID-19.¹ It is important to note, however, that this development does not mean that the need for plasma donations has diminished. Both normal source plasma donations, from healthy individuals, and convalescent plasma donations, from individuals who have recovered from COVID-19, are still needed to fight COVID-19 and the many non-COVID-19 conditions (e.g., immune deficiencies and blood clotting disorders) for which plasma protein therapies are ordinarily used.
Read More

1
2
3

› ‹

The Source, the international magazine of the plasma protein therapeutics industry, is published quarterly.

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Media and Information

Advocacy

Copyright © 2020 PPTA. All rights reserved. (202) 789-3100

Terms of Use | Privacy Statement | Sitemap